Making Sure That Orphan Incentives Tip the Right Way in Europe
Authors:
- Denis HorganDHDenis Horgan
- Jasmina Koeva-BalabanovaJKJasmina Koeva-Balabanova
- Ettore CapoluongoEttore Capoluongo
- Beata JagielskaBJBeata Jagielska
- Ivana CattaneoICIvana Cattaneo
- Marta KozaricMKMarta Kozaric
- Birute TumieneBTBirute Tumiene
- Jean-Paul El AhlJAJean-Paul El Ahl
- Jonathan A. LalJLJonathan A. Lal
- Dipak KalraDKDipak Kalra
- Núria MalatsNMNúria Malats
Open Access
- 23 August 2022
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1600
Abstract
The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that could—in addition to the intrinsic complexities of research—reduce the incentives on which commercial activity in this area is dependent. The European Union review of its pharmaceutical legislation, for which proposals are scheduled to appear before the end of 2022, envisages adjusting the decade-old incentives to meet objectives that are more precisely targeted. However, researchers, physicians, patients and industry have expressed concerns that ill-considered modifications could have unintended consequences in disrupting the current balance and could reduce rather than increase the flow of innovative treatments for rare diseases.Keywords
This publication has 49 references indexed in Scilit:
- Rare Diseases ResearchChest, 2013
- Clinical evidence for orphan medicinal products-a cause for concern?Orphanet Journal of Rare Diseases, 2013
- Challenges to orphan drugs access in Eastern Europe: The case of BulgariaHealth Policy, 2012
- Orphan drug development: an economically viable strategy for biopharma R&DDrug Discovery Today, 2012
- European regulation on orphan medicinal products: 10 years of experience and future perspectivesNature Reviews Drug Discovery, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Rare diseases, orphan drugs and their regulation: questions and misconceptionsNature Reviews Drug Discovery, 2010
- Issues Surrounding Orphan Disease and Orphan Drug Policies in EuropeApplied Health Economics and Health Policy, 2010
- Orphan drug: Development trends and strategiesJournal of Pharmacy and Bioallied Sciences, 2010
- Orphan drug development is not taking offBritish Journal of Clinical Pharmacology, 2009